Journal of Diagnostics Concepts & Practice >

2023 , Vol. 22 >Issue 03: 306 - 310

DOI: https://doi.org/10.16150/j.1671-2870.2023.03.16

Review articles

Advances in laboratory diagnosis of autoimmune bullous dermatoses

Expand
  • Department of Dermatology, Ruijin Hospital， Shanghai Jiao Tong University School of Medicine, Shanghai 200025

Received date: 2022-02-01

  Online published: 2023-11-17

Fold

Abstract

Autoimmune bullous dermatoses (AIBD) are associated with autoantibodies against structural components in the skin and mucous membranes. Pemphigus diseases are associated with autoantibodies against the components of desmoglein, while pemphigoid diseases are associated with autoantibodies targeting the structural proteins of the dermal‐epidermal junction. Depending on the components targeted by the autoimmune system, treatments for the two types of diseases are different, so laboratory diagnosis is required for identification. Traditional laboratory diagnosis methods include direct immunofluorescence (DIF), indirect immunofluorescence (IIF), enzyme‐linked immunosorbent assay (ELISA) and immunoblotting (IBT). In recent years, new technologies have emerged. The low‐cost and efficient BIOCHIP technology simplifies the interpretation of IIF, and detection rates of Dsg3 and BP180 are as high as 97%-100% and 94% respectively. EUROTideTM technology is more sensitive and specific than traditional DIF methods, with less background fluorescence. MESACUP anti-Skin profile TEST (ASPT) can detect multiple antibodies simultaneously, and the detection specificity for Dsg1 and Dsg3 reaches 100%. Lateral flow immunoassay (LFIA) can be used for rapid qualitative testing and results can be checked visually. Chemiluminescence enzyme immunoassay is highly automated and efficient, with 94%-99% compliance rate compared with ELISA. Fluorescence overlay antigen mapping using laser‐scanning confocal microscopy (FOAM‐LSCM) can differentially stain different components of the skin basement membrane zone by one‐ime, which is more efficient than the traditional manual DIF method, and is useful for diagnosing the AIBD that is difficult to differentiate from bullous pemphigoid or acquired epidermolysis bullosa under traditional methods. Laboratory diagnostic technology plays an important role in the treatment and prognosis of AIBD. Based on traditional laboratory methods, this article compares and discusses the value of new technologies in the diagnosis of AIBD.

Key words： Autoimmune bullous dermatoses; Direct immunofluorescence assay; Bullous pemphigoid antigen 180; Laboratory

Cite this article

WU Xinyi, PAN Meng, ZHUN Haiqin . Advances in laboratory diagnosis of autoimmune bullous dermatoses[J]. Journal of Diagnostics Concepts & Practice, 2023 , 22(03) : 306 -310 . DOI: 10.16150/j.1671-2870.2023.03.16

References

[1] SCHMIDT E, KASPERKIEWICZ M, JOLY P. Pemphigus[J]. The Lancet, 2019, 394(10201):882-894.
[2] SCHMIDT E, ZILLIKENS D. Pemphigoid diseases[J]. The Lancet, 2013, 381(9863):320-332.
[3] ALPSOY E, AKMAN-KARAKAS A, UZUN S. Geographic variations in epidemiology of two autoimmune bullous diseases: pemphigus and bullous pemphigoid[J]. Arch Dermatol Res, 2015, 307(4):291-298.
[4] PORRO A M, SEQUE C A, FERREIRA M C C, et al. Pemphigus vulgaris[J]. An Bras Dermatol, 2019, 94(3):264-278.
[5] EGAMI S, YAMAGAMI J, AMAGAI M. Autoimmune bullous skin diseases, pemphigus and pemphigoid[J]. J Allergy Clin Immunol, 2020, 145(4):1031-1047.
[6] MIYAMOTO D, SANTI C G, AOKI V, et al. Bullous pemphigoid[J]. An Bras Dermatol, 2019, 94(2):133-146.
[7] KRIDIN K, LUDWIG R J. The Growing Incidence of Bullous Pemphigoid: Overview and Potential Explanations[J]. Front Med (Lausanne), 2018, 5:220.
[8] DANIEL B S, MURRELL D F. Review of autoimmune blistering diseases: the Pemphigoid diseases[J]. J Eur Acad Dermatol Venereol, 2019, 33(9):1685-1694.
[9] SASCHENBRECKER S, KARL I, KOMOROWSKI L, et al. Serological Diagnosis of Autoimmune Bullous Skin Diseases[J]. Front Immunol, 2019, 10:1974.
[10] 刘红芳, 薛汝增, 潘慧清, 等. 80例大疱性皮肤病组织病理及直接免疫荧光结果分析[J]. 皮肤性病诊疗学杂志, 2010, 17(3):179-181.
[10] LIU H F, XUE R Z, PAN H Q, et al. Analysis of pathology and direct immunofluorescence test on 80 cases of bullous dermatosis[J]. J Diagn Ther on Derm Venereol, 2010, 17(3):179-181.
[11] KNEISEL A, HERTL M. Autoimmune bullous skin diseases. Part 1: Clinical manifestations[J]. J Dtsch Dermatol Ges, 2011, 9(10):844-856.
[12] 马俊兵, 杨丽颖. 80例大疱性皮肤病组织病理及直接免疫荧光结果分析[J]. 中国农村卫生, 2017(2):71-72.
[12] MA J B, YANG L Y. Analysis of pathology and direct immunofluorescence test on 80 cases of bullous dermatosis[J]. Chin Rural Health, 2017(2):71-72.
[13] SáRDY M, KOSTAKI D, VARGA R, et al. Comparative study of direct and indirect immunofluorescence and of bullous pemphigoid 180 and 230 enzyme-linked immunosorbent assays for diagnosis of bullous pemphigoid[J]. J Am Acad Dermatol, 2013, 69(5):748-753.
[14] GIURDANELLA F, DIERCKS G F, JONKMAN M F, et al. Laboratory diagnosis of pemphigus: direct immunofluorescence remains the gold standard[J]. Br J Dermatol, 2016, 175(1):185-186.
[15] 李卫平, 潘萌, 薛峰, 等. 免疫印迹法与免疫荧光法检测寻常型天疱疮自身抗体的比较[J]. 上海免疫学杂志, 2003, 23(1):43-44.
[15] LI W P, PAN M, XUE F, et al. Comparison of Immunoblot and Immunofluorescence in Detecting Pemphigus Vulgaris Antibodies[J]. Shanghai J Immunol, 2003, 23(1):43-44.
[16] KRIDIN K, BERGMAN R. The usefulness of indirect immunofluorescence in pemphigus and the natural history of patients with initial false-positive results: a retrospective cohort study[J]. Front Med (Lausanne), 2018, 5:266.
[17] DI LERNIA V, CASANOVA D M, GOLDUST M, et al. Pemphigus Vulgaris and Bullous Pemphigoid: Update on Diagnosis and Treatment[J]. Dermatol Pract Concept, 2020, 10(3):e2020050.
[18] 许人超, 郑捷, 潘萌, 等. 酶联免疫吸附法和免疫印迹技术检测天疱疮抗体的比较[J]. 中国皮肤性病学杂志, 2012, 26(5):452-454.
[18] XU R C, ZHENG J, PAN M, et al. Comparison of enzyme-linked immunosorbent assay test with immunoblot assay in the diagnosis of pemphigus[J]. Chin J Derm Venereol, 2012, 26(5):452-454.
[19] XUAN R R, YANG A, MURRELL D F. New biochip immunofluorescence test for the serological diagnosis of pemphigus vulgaris and foliaceus: A review of the literature[J]. Int J Womens Dermatol, 2018, 4(2):102-108.
[20] WITTE M, ZILLIKENS D, SCHMIDT E. Diagnosis of Autoimmune Blistering Diseases[J]. Front Med (Lausanne), 2018, 5:296.
[21] MEIJER J M, DIERCKS G F H, DE LANG E W G, et al. Assessment of Diagnostic Strategy for Early Recognition of Bullous and Nonbullous Variants of Pemphigoid[J]. JAMA Dermatol, 2019, 155(2):158-165.
[22] SCHMIDT E, D?HNRICH C, ROSEMANN A, et al. Novel ELISA systems for antibodies to desmoglein 1 and 3: correlation of disease activity with serum autoantibody levels in individual pemphigus patients[J]. Exp Dermatol, 2010, 19(5):458-463.
[23] TAMPOIA M, ZUCANO A, VILLALTA D, et al. Anti-skin specific autoantibodies detected by a new immunofluorescence multiplex biochip method in patients with autoimmune bullous diseases[J]. Dermatology, 2012, 225(1):37-44.
[24] SADIK C D, PAS H H, BOHLMANN M K, et al. Value of biochip technology in the serological diagnosis of pemphigoid gestationis[J]. Acta Derm Venereol, 2017, 97(1):128-130.
[25] VAN BEEK N, KRüGER S, FUHRMANN T, et al. Multicenter prospective study on multivariant diagnostics of autoimmune bullous dermatoses using the BIOCHIP technology[J]. J Am Acad Dermatol, 2020, 83(5):1315-1322.
[26] LEMCKE S, SOKOLOWSKI S, RIECKHOFF N, et al. Automated direct immunofluorescence analyses of skin biopsies[J]. J Cutan Pathol, 2016, 43(3):227-235.
[27] HORVáTH O N, VARGA R, KANEDA M, et al. Diagnostic performance of the “MESACUP anti-Skin profile TEST”[J]. Eur J Dermatol, 2016, 26(1):56-63.
[28] SCHMIDT T, MAURACHER S, BENDER L. et al. A novel lateral flow immunoassay for the rapid detection of anti-Dsg3 IgG serum autoantibodies in pemphigus vulgaris[J]. Exp Dermatol, 2018, 27(3):233-237.
[29] FUJIO Y, KOJIMA K, HASHIGUCHI M, et al. Validation of chemiluminescent enzyme immunoassay in detection of autoantibodies in pemphigus and pemphigoid[J]. J Dermatol Sci, 2017, 85(3):208-215.
[30] TANAKA R, TAKEMURA M, SATO M, et al. Comparison of chemiluminescence enzyme immunoassay (CLEIA) with ELISA for the determination of anti-cyclic citrullinated peptide antibodies[J]. Clin Chim Acta, 2010, 411(1-2):22-25.
[31] WOZNIAK K, JAKUBOWSKA B, KALINSKA-BIENIAS A, et al. Diagnosis of autoimmune subepidermal bullous diseases with mucous membrane involvement based on laser-scanning confocal microscopy[J]. Eur J Dermatol, 2020, 30(5):516-523.
[32] WOZNIAK K, KAZAMA T, KOWALEWSKI C. A practical technique for differentiation of subepidermal bullous diseases: localization of in vivo-bound IgG by laser scanning confocal microscopy[J]. Arch Dermatol, 2003, 139(8):1007-1011.
[33] PROST-SQUARCIONI C, CAUX F, SCHMIDT E, et al. International Bullous Diseases Group: consensus on diagnostic criteria for epidermolysis bullosa acquisita[J]. Br J Dermatol, 2018, 179(1):30-41.
[34] KITAYAMA S, MAKINO T, HAYASHI M, et al. Usefulness of immunofluorescence overlay antigen mapping in the identification of autoantigen in anti-p200 pemphigoid[J]. J Dermatol, 2023, 50(9):1194-1198.
Options
Outlines

/

〈 〉